---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-017852"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:36:26.250064+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q1 revenue $38.6M (+0.5% YoY); net loss widens to $62.8M

## Summary
- clonoSEQ test volume grew 45% YoY and 12% QoQ; MRD regulatory milestone revenue of $3.0M from partner drug approval.
- T-Detect Lyme sensitivity 54% vs SOC 30% at 99% specificity; launch planned for 2022 Lyme season.
- Entered T-MAP collaboration with Janssen for RSV vaccine program; appointed Tycho Peterson as CFO.
- Revenue guidance for FY2022 reaffirmed at $185-195M; cash and securities $500.7M as of March 31.

## SEC filing metadata
- accession: 0001564590-22-017852
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000156459022017852/0001564590-22-017852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000156459022017852/adpt-8k_20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-017852
- JSON: https://secwatch.observer/filing/0001564590-22-017852.json
- Plain text: https://secwatch.observer/filing/0001564590-22-017852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.